Recce Pharmaceuticals develops burn wound gel for the US Army — Capital Brief

Recce Pharmaceuticals develops burn wound gel for the US Army — Capital Brief

February 1, 2026 discoverhiddenusacom Health

A cooperative research and development agreement (CRADA) has been established between Recce Pharmaceuticals and the United States Army Institute of Surgical Research (USAISR). The agreement centres on evaluating the effectiveness of Recce 372, a burn wound gel developed by Recce Pharmaceuticals.

Burn Wound Infections and the Need for New Treatments

Burn wound infections represent a significant threat to patient survival and are increasingly challenging to treat. Rising antimicrobial resistance complicates the management of these infections. The US government has demonstrated a commitment to addressing this issue through funding of clinical partnerships aimed at developing new therapeutic options.

Did You Know? Burn wound infections are a leading cause of mortality among burn patients.

Evaluating Recce 372

The study undertaken through this CRADA will specifically assess Recce 372’s ability to reduce bacterial pathogens commonly associated with burn wound infections. This research builds upon an existing collaboration between Recce Pharmaceuticals and the United States Army Medical Research Institute of Infectious Diseases.

Expert Insight: The US government’s continued investment in partnerships like this highlights the critical need for innovative solutions to combat antibiotic resistance, a growing global health concern. The expansion of research into multiple applications suggests a broadening recognition of the potential benefits of this therapeutic approach.

According to James Graham, CEO of Recce Pharmaceuticals, the new agreement, alongside the existing collaboration, indicates increasing interest from the US government in R327 across various applications.

Frequently Asked Questions

What is the purpose of the CRADA?

The CRADA is to evaluate the effectiveness of Recce 372, a burn wound gel, in reducing bacterial pathogens associated with burn wound infections.

Who are the parties involved in this agreement?

The parties involved are Recce Pharmaceuticals and the United States Army Institute of Surgical Research (USAISR).

What has Recce Pharmaceuticals said about this agreement?

James Graham, CEO of Recce Pharmaceuticals, stated that the agreement demonstrates accelerating US government interest in R327 across multiple operational and therapeutic applications.

What role might further research play in addressing the challenges posed by antimicrobial resistance?

,